Alumis to Present Promising Data on TYK2 Inhibitor at ACTRIMS 2025

Alumis Inc., a biopharmaceutical company focused on precision medicine for immune-related diseases, is set to present new data on A-005, its promising TYK2 inhibitor, at the ACTRIMS Forum 2025. The company’s research highlights A-005’s ability to penetrate the central nervous system (CNS) and effectively inhibit TYK2-specific signaling, a key factor in neuroinflammatory diseases like multiple sclerosis (MS). According to Chief Medical Officer Dr. Jörn Drappa, the Phase 1 data confirms A-005’s strong safety profile and potent inhibition of pro-inflammatory cytokines, laying the groundwork for further clinical development.

With plans to launch a Phase 2 clinical trial in MS patients later this year, Alumis sees A-005 as a potential game-changer in treating CNS inflammation. The drug’s ability to cross the blood-brain barrier and precisely target immune pathways could set it apart from existing therapies. As the first reported allosteric TYK2 inhibitor with CNS penetration, A-005 represents a novel approach that could transform treatment strategies for multiple sclerosis and other neuroinflammatory conditions.